Amy Miller, executive VP of the Personalized Medicine Coalition, will join the Society for Women's Health Research as its new CEO starting Jan. 3, 2017.
SWHR has been advocating for greater inclusion of women in health research for more than 25 years. The organization's efforts were instrumental to the National Institutes of Health issuing guidelines requiring women be included in clinical research; to the passage of the 1993 NIH Revitalization Act, which mandated sex-based analysis in Phase III clinical trials; and to the US Food and Drug Administration putting out guidelines requiring women's participation in early drug efficacy studies.
"We welcome Amy to lead SWHR at a critical crossroads in women’s health research," SWHR Founder Florence Haseltine said in a statement. "While we celebrate the many achievements in women’s health policy advocacy to date, we must continue to press for unlocking the mysteries in sex differences and how men and women are different when it comes to cures, treatments and prevention."
Miller's tenure at PMC has primed her to lead SWHR. At PMC, she worked with stakeholders accross academia, industry, and governement to support policies that would spur devleopment and adoption of diagnostics and peronalized drugs that capitalize on biological differences among individuals. Previously, at the office of the Director of the National Institute of Mental Health, Miller worked to connect researchers, legislators, patients, and their families. She was also a fellow at the American Association for the Advancement of Science and domestic policy advisor to Senator Jay Rockefeller.